MedTrace Logo

Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma

NCT06429865 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2024-05-28

No results posted yet for this study

Summary

cytosponge has good diagnostic efficacy in the diagnosis of esophageal cancer, and is more safe, economic and comfortable. It is expected to replace gastroscope in the surveillance after endoscopic submucosal dissection to a certain extent. At present, there is no relevant research at home and abroad. This study plans to establish a large sample cohort based on the collaborative research network established earlier, prospectively include 1000 patients who received endoscopic submucosal dissection for esophageal squamous cell carcinoma and compare the effectiveness and safety of cytosponge and gastroscope in surveillance after endoscopic submucosal dissection for esophageal squamous cell carcinoma through self -comparison.

Conditions

Interventions

DIAGNOSTIC_TEST

cytosponge

Use of cytosponge as a tool to patients who need surveillance after endoscopic submucosal dissection for esophageal squamous cell carcinoma

Sponsors & Collaborators

  • Tongliao City Hospital

    collaborator UNKNOWN

  • Ankang Central Hospital

    collaborator OTHER

  • Yancheng First People's Hospital

    collaborator OTHER

  • Lianshui County People's Hospital

    collaborator UNKNOWN

  • Nanchong Central Hospital

    collaborator OTHER_GOV

  • Henan Provincial People's Hospital

    collaborator OTHER

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Zhongda Hospital

    collaborator OTHER

  • Affiliated hospital of nanjing university hospital of Chinese medicine

    collaborator UNKNOWN

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Luowei Wang, MD · Changhai Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06429865 on ClinicalTrials.gov